Kynurenine System and Multiple Sclerosis, Pathomechanism and Drug Targets with An Emphasis on Laquinimod

E-ISSN： 1873-5592|19|7|805-814

ISSN： 1389-4501

Source： Current Drug Targets, Vol.19, Iss.7, 2018-04, pp. : 805-814

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Review of laquinimod and its therapeutic potential in multiple sclerosis

By Thöne Jan Gold Ralf

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 18, 2013-12 ,pp. : 2545-2552

Informa Healthcare

Access to resources Recommend Favorite

Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis

By Thööne Jan Gold Ralf

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 3, 2011-03 ,pp. : 365-370

Informa Healthcare

Access to resources Recommend Favorite

Recent Advances in the Treatment of Amyotrophic Lateral Sclerosis. Emphasis on Kynurenine Pathway Inhibitors

Central Nervous System Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Central Nervous System Agents), Vol. 9, Iss. 1, 2009-03 ,pp. : 32-39

Bentham Science Publishers

Access to resources Recommend Favorite

Current Nervous System Related Drug Targets for the Treatment of Amyotrophic Lateral Sclerosis

Current Pharmaceutical Design, Vol. 16, Iss. 18, 2010-06 ,pp. : 2053-2073

Bentham Science Publishers

Access to resources Recommend Favorite

Current Immune Therapies of Autoimmune Disease of the Nervous System with Special Emphasis to Multiple Sclerosis

Current Pharmaceutical Design, Vol. 18, Iss. 29, 2012-10 ,pp. : 4513-4517

Bentham Science Publishers

Access to resources Recommend Favorite